94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Oncol.
Sec. Gastrointestinal Cancers: Colorectal Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1558470
This article is part of the Research Topic Cancer Biology, Immunotherapy and Aging View all 7 articles
TAS-102 in combination with bevacizumab for second-line treatment of advanced metastatic colorectal cancer with a hypertensive elderly patient: A case report
Provisionally accepted- Department of Medical Oncology, Second Affiliated Hospital of Dalian Medical University, Dalian, China
Background: Colorectal cancer (CRC) is one of the common malignant tumors worldwide. Approximately 20-25% of patients have metastases at the time of initial diagnosis and nearly half eventually develop metastatic cancer. The standard first-and second-line treatment for unresectable metastatic CRC is full-dose two-/three-agent chemotherapy with or without combination of molecularly targeted agents. However, many patients are ineligible for intensive therapy due to poor performance status or advanced age. TAS-102 in combination with bevacizumab may provide a new treatment idea for patients with advanced CRC who are ineligible for intensive therapy.We report a case of a 91-year-old woman diagnosed with stage IV adenocarcinoma of the rectosigmoid junction, in the presence of multiple metastases. The patient had a history of hypertension, had suffered from deep vein thrombosis of the left lower extremity, and was allergic to several drugs. Genetic testing showed multiple mutations in KRAS, PIK3CA, and TP53, microsatellite stability, and a tumor mutational burden of 4.5 Mut/Mb. The patient was diagnosed with stage IV adenocarcinoma of the rectosigmoid junction in May 2020, with a clinical stage of cTxNxM1. Without surgery, patient received first-line treatment with capecitabine in combination with bevacizumab, which was changed to second-line treatment with TAS-102 in combination with bevacizumab after disease progression, with a progression free survival of 10 months, achieving a significant survival benefit. Later, due to the patient's poor physical condition, no further medication was administered, and the patient died on September 1, 2022.Conclusion：TAS-102 in combination with bevacizumab for the treatment of elderly patients with advanced metastatic CRC who are ineligible for intensive therapy is a promising treatment option.
Keywords: TAS-102, bevacizumab, case report, Metastatic colorectal cancer, MCRC, elderly patient, Second-line
Received: 10 Jan 2025; Accepted: 03 Mar 2025.
Copyright: © 2025 Xu, Qiu, He, Liu, He and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jinghua Sun, Department of Medical Oncology, Second Affiliated Hospital of Dalian Medical University, Dalian, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.